Why the study?
Large cohort studies of pregnant women with HCM are limited, and management practices vary across centres without protocolized care.
This review underscores the unique cardiovascular challenges of managing hypertrophic cardiomyopathy during pregnancy and calls for standardized care protocols to optimize maternal and fetal outcomes.
Answers are grounded in this paper and cite their sources.
Management of pregnant women with HCM varies without standardized protocols; leaves open the need for prospective studies to inform care.
Hypertrophic cardiomyopathy (HCM) is a common inherited genetic cardiac disorder that increasingly is being diagnosed in people of childbearing age, due to advancements in genetic testing and the evolution of screening guidelines. Many women may first present with HCM during pregnancy, which can lead to adverse maternal and fetal outcomes if not appropriately managed. Although most women with HCM tolerate pregnancy well, it can be associated with increased cardiovascular risks, including heart failure, arrhythmias, and adverse fetal outcomes, particularly among those with suboptimal baseline functional status. Medical therapy remains the mainstay of management of HCM in pregnancy, as only a limited number of studies have been done on the safety and effectiveness of invasive procedures, such as alcohol septal ablation and cardiac myomectomy, in pregnant women. Large cohort studies of women with HCM are very limited, and management practices vary within centres, with no protocolized care. This review aims to summarize the unique challenges faced by pregnant women with HCM, highlighting the need for large multicentric studies and more standardized care protocols to optimize maternal and fetal outcomes.
No takes yet. Share an insight, caveat, or question.
Mehta et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: